US EditionTeva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; ...
- Teva Pharmaceutical Industries Ltd. Announced on May 20, 2025, in Tel Aviv that it upsized and priced approximately $2.3 billion equivalent of senior notes.
- The upsizing from the prior $2 billion offering aims to fund tender offers to purchase several outstanding senior notes and repay other debts.
- The Notes consist of £1 billion at 4.125% maturing in 2031, $700 million at 5.750% maturing in 2030, and $500 million at 6.000% maturing in 2032, all unsecured and senior obligations.
- Teva expects to settle the Notes around May 28, 2025, subject to closing conditions, and the offering was registered with the SEC on February 7, 2025.
- No assurance exists that the transactions will complete, as forward-looking statements note risks including indebtedness limits and possible credit rating impacts.
11 Articles
11 Articles
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; ...
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount…
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt - Teva Pharmaceutical Indus (NYSE:TEVA)
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the "Notes"). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i…
Muskoka Region
TheIFP.caTeva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount…
Cambridge Times
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB.
Coverage Details
Bias Distribution
- 70% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
